Cross-Sex Hormone Therapy for Gender Dysphoria

The document from 2014 reviews cross-sex hormone therapy (CHT) for individuals with gender dysphoria, discussing the administration of testosterone and estrogen for female-to-male (FtM) and male-to-female (MtF) transitions, respectively. It outlines the physical changes expected from hormone therapy, the importance of monitoring hormone levels, and managing associated risks such as cardiovascular disease and cancer. The document also emphasizes the need for informed consent due to irreversible physical changes, the lack of transgender medicine in medical curricula, and the importance of culturally sensitive training for healthcare professionals. It highlights that while CHT has not been proven to increase mortality and morbidity, careful screening for potential complications is necessary, and continuous medical supervision is recommended. The document concludes with the need for education and training for healthcare providers and the importance of guidelines to improve the management of gender dysphoria.